SNS Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

SNS Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Buy	+607	New	+$269K	0.01%	462

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SNS Financial Group's VRTX Position: Q2 2026 in Review

SNS Financial Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 607 shares worth $302K. The stake represents 0.01% of the portfolio and ranks #462 among its holdings.

1,436 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

SNS Financial Group held 607 shares of Vertex Pharmaceuticals worth $302K as of Q2 2026.
Vertex Pharmaceuticals was a new SNS Financial Group position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of SNS Financial Group's portfolio in Q2 2026, its #462 holding.
1,436 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SNS Financial Group's 13F filing for Q2 2026, filed 11 Aug 2026.